Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, Mcconkey DJ, Bivalacqua TJ.

Oncol Lett. 2019 Nov;18(5):4923-4929. doi: 10.3892/ol.2019.10786. Epub 2019 Aug 29.

2.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
3.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

4.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
5.

Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?

Burger M, Kamat AM, McConkey D.

Eur Urol Oncol. 2019 Aug 6. pii: S2588-9311(19)30093-8. doi: 10.1016/j.euo.2019.06.012. [Epub ahead of print]

6.

Does it matter whether a T1 high-grade tumor is molecularly classified?

Stenzl A, McConkey D, Bellmunt J.

Eur Urol Oncol. 2019 Aug 3. pii: S2588-9311(19)30112-9. doi: 10.1016/j.euo.2019.07.009. [Epub ahead of print]

7.

Predictive biomarkers for drug response in bladder cancer.

Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ.

Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082. [Epub ahead of print] Review.

PMID:
31370109
8.

Clinical implications of molecular subtyping in bladder cancer.

Satyal U, Sikder RK, McConkey D, Plimack ER, Abbosh PH.

Curr Opin Urol. 2019 Jul;29(4):350-356. doi: 10.1097/MOU.0000000000000641.

PMID:
31158107
9.

Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?

Meeks JJ, McConkey DJ.

Eur Urol. 2019 Aug;76(2):207-208. doi: 10.1016/j.eururo.2019.05.025. Epub 2019 May 31. No abstract available.

PMID:
31155339
10.

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.

Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE 3rd, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP.

Oncoimmunology. 2019 Feb 20;8(5):e1577125. doi: 10.1080/2162402X.2019.1577125. eCollection 2019.

11.

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.

Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE 3rd, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

Cell Rep. 2019 May 7;27(6):1781-1793.e4. doi: 10.1016/j.celrep.2019.04.048.

12.

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP.

Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.

PMID:
30851984
13.

Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis.

Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B.

Cell Rep. 2019 Feb 19;26(8):2241-2256.e4. doi: 10.1016/j.celrep.2019.01.095.

14.

SIU-ICUD consultation on bladder cancer: basic science.

McConkey DJ, Lerner SP.

World J Urol. 2019 Jan;37(1):15-29. doi: 10.1007/s00345-018-2594-y. Epub 2018 Dec 13. Review.

PMID:
30547196
15.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D.

Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available.

16.

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.

Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.

17.

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP.

World J Urol. 2019 Oct;37(10):2041-2049. doi: 10.1007/s00345-018-2553-7. Epub 2018 Nov 11. Review.

PMID:
30415317
18.

ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.

Choi W, McConkey DJ.

Eur Urol. 2019 Feb;75(2):240-241. doi: 10.1016/j.eururo.2018.09.043. Epub 2018 Oct 23. No abstract available.

PMID:
30366635
19.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

20.

Molecular Subtypes of Bladder Cancer.

McConkey DJ, Choi W.

Curr Oncol Rep. 2018 Aug 20;20(10):77. doi: 10.1007/s11912-018-0727-5. Review.

PMID:
30128829
21.

Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research.

Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ.

Urol Oncol. 2019 May;37(5):313-317. doi: 10.1016/j.urolonc.2018.06.008. Epub 2018 Aug 13. Review.

PMID:
30115512
22.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

23.

Organoid culture of bladder cancer cells.

Yoshida T, Singh AK, Bishai WR, McConkey DJ, Bivalacqua TJ.

Investig Clin Urol. 2018 May;59(3):149-151. doi: 10.4111/icu.2018.59.3.149. Epub 2018 Apr 30. No abstract available.

24.

HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells.

White MC, Schroeder RD, Zhu K, Xiong K, McConkey DJ.

Oncogene. 2018 Aug;37(32):4413-4427. doi: 10.1038/s41388-018-0227-y. Epub 2018 May 3.

25.

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, McConkey DJ, Bivalacqua TJ.

Oncotarget. 2018 Jan 24;9(13):11060-11070. doi: 10.18632/oncotarget.24308. eCollection 2018 Feb 16.

26.

Subtyping Bladder Cancers: Biology vs Bioinformatics.

McConkey DJ, Choi W.

J Natl Cancer Inst. 2018 May 1;110(5):439-440. doi: 10.1093/jnci/djx254. No abstract available.

PMID:
29342301
27.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jul;200(1):68-73. doi: 10.1016/j.juro.2017.12.054. Epub 2018 Jan 4.

PMID:
29307680
28.

Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line.

Yoshida T, Kates M, Sopko NA, Liu X, Singh AK, Bishai WR, Joice G, McConkey DJ, Bivalacqua TJ.

Urol Oncol. 2018 Apr;36(4):160.e23-160.e32. doi: 10.1016/j.urolonc.2017.11.024. Epub 2017 Dec 26.

PMID:
29288005
30.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18.

PMID:
29055653
31.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

32.

Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells.

Schroeder RD, Choi W, Hong DS, McConkey DJ.

Oncotarget. 2017 Jun 7;8(31):51675-51687. doi: 10.18632/oncotarget.18386. eCollection 2017 Aug 1.

33.

Effects of thiazolidinedione in patients with active bladder cancer.

Li R, Metcalfe MJ, Ferguson JE 3rd, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM.

BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23.

34.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

35.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C.

Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13.

36.

Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer.

Pal SK, Pham A, Vuong W, Liu X, Lin Y, Ruel N, Yuh BE, Chan K, Wilson T, Lerner SP, McConkey D, Jove R, Liang W.

Eur Urol Focus. 2017 Feb;3(1):130-135. doi: 10.1016/j.euf.2016.03.003. Epub 2016 Mar 25.

PMID:
28720358
37.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

38.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
39.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

40.

The integrated stress response and proteotoxicity in cancer therapy.

McConkey DJ.

Biochem Biophys Res Commun. 2017 Jan 15;482(3):450-453. doi: 10.1016/j.bbrc.2016.11.047. Epub 2017 Feb 3. Review.

41.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

42.

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.

Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ.

Oncotarget. 2016 Dec 6;7(49):80164-80174. doi: 10.18632/oncotarget.13284.

43.

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25.

44.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.

Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

45.

Intrinsic subtypes and bladder cancer metastasis.

McConkey DJ, Choi W, Ochoa A, Dinney CPN.

Asian J Urol. 2016 Oct;3(4):260-267. doi: 10.1016/j.ajur.2016.09.009. Epub 2016 Sep 23. Review.

46.

Biology and therapy of urological cancer metastasis.

Posadas EM, McConkey DJ, Chung LWK.

Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. No abstract available.

47.

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.

Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C.

Oncotarget. 2017 May 23;8(21):34205-34222. doi: 10.18632/oncotarget.11009.

48.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

49.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

50.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B.

Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.

Supplemental Content

Loading ...
Support Center